(-0.10%) 5 463.61 points
(0.07%) 39 139 points
(0.08%) 17 732 points
(-0.04%) $80.80
(-5.04%) $2.62
(-0.87%) $2 310.60
(-0.30%) $28.78
(3.19%) $1 017.90
(0.35%) $0.936
(0.75%) $10.68
(0.54%) $0.793
(-0.27%) $87.26
Live Chart Being Loaded With Signals
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders...
Stats | |
---|---|
Dagens volum | 170 627 |
Gjennomsnittsvolum | 0 |
Markedsverdi | 40.85M |
EPS | $-0.310 ( Q3 | 2022-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.684 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.104 (10.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-02-10 | Aberman Zami | Buy | 80 616 | Common Stock |
2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 122 663 | Common Stock |
2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 22 015 | Common Stock |
2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 71 775 | Common stock |
2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 24 110 | Common stock |
INSIDER POWER |
---|
0.00 |
Last 98 transactions |
Buy: 11 245 290 | Sell: 1 084 851 |
Volum Korrelasjon
Pluristem Therapeutics Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Pluristem Therapeutics Korrelasjon - Valuta/Råvare
Pluristem Therapeutics Økonomi
Annual | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.770 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.770 |
FY | 2020 |
Omsetning: | $23 000.00 |
Bruttogevinst: | $23 000.00 (100.00 %) |
EPS: | $-1.600 |
FY | 2019 |
Omsetning: | $54 000.00 |
Bruttogevinst: | $52 000.00 (96.30 %) |
EPS: | $-2.90 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Pluristem Therapeutics
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA\'s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.